Skip to the main content

Gynaecologia et perinatologia : journal for gynaecology, perinatology, reproductive medicine and ultrasonic diagnostics, Vol. 27 No. 3-4, 2018.

Case report

Pregnancy outcome and liraglutide levels in serum and umbilical vein blood of a woman with type 2 diabetes. A case report

Marina Ivanišević orcid id orcid.org/0000-0001-6478-1174 ; Department of Obstetrics and Gynecology, Hospital Medical Center Zagreb, School of Medicine University of Zagreb
Mislav Herman ; Department of Obstetrics and Gynecology, Hospital Medical Center Zagreb, School of Medicine University of Zagreb
Marina Horvatiček ; Ruđer Bošković Institute Zagreb
Marijana Vučić Lovrenčić ; Institute of Clinical Chemistry and Laboratory Medicine, Merkur Teaching Hospital, Zagreb, Croatia
Josip Đelmiš ; Department of Obstetrics and Gynecology, Hospital Medical Center Zagreb, School of Medicine University of Zagreb

Full text: english pdf 708 Kb

page 70-72

downloads: 656

cite

Abstract

Background: According to FDA guidelines, liraglutide should be used on the basis of careful consideration in pregnant women with Type 2 diabetes mellitus. The aim of the present study was to record the concentration of liraglutide in maternal and umbilical vein serum from a pregnant woman treated with liraglutide. Case report: The pregnant woman we present in this case report is a 28-year-old diagnosed with Type 2 diabetes mellitus for 7 years. In spite of high insulin dose her glycaemia was poorly controlled, she developed dyslipidaemia and her body weight increased; thus, her diabetologist prescribed liraglutide injections and metformin. At booking, obstetrical ultrasound confirmed intrauterine pregnancy of 8 gestational weeks. The patient was informed about all possible consequences for her foetus that might be caused by liraglutide therapy during pregnancy. She continued her treatment with liraglutide and metformin medication throughout pregnancy. Her pregnancy was terminated by elective Caesarean section at 39 gestational weeks; a healthy newborn male was delivered. The concentration of liraglutide was measured in maternal and umbilical vein serum. Conclusion: There was no significant transfer of liraglutide from the circulation of the treated mother to her fetus, at least 3.5 h after the drug application.

Keywords

Pregnancy; Type 2 diabetes mellitus; liraglutide

Hrčak ID:

251874

URI

https://hrcak.srce.hr/251874

Publication date:

1.7.2018.

Visits: 1.063 *